FrancophonIA/ELRC3.0 huggingface dataset:
English: Pre-medication with anti-pyretic and anti-histamine is recommended for the first POTELIGEO infusion.
Slovenian: Pri prvi infuziji zdravila POTELIGEO se priporoča predhodno zdravljenje z antipiretikom in antihistaminikom.
English: What POTELIGEO looks like and contents of the pack
Slovenian: Izgled zdravila POTELIGEO in vsebina pakiranja
English: In general, IgG molecules are known to cross the placental barrier and mogamulizumab concentrations in foetus plasma were detected.
Slovenian: Na splošno je znano, da molekule IgG prehajajo skozi placentarno pregrado.
English: Based on a population PK analysis, the geometric mean [% coefficient of variation (CV%)] central volume of distribution (Vc) was 3.57 L (20.1%).
Slovenian: osrednjega volumna porazdelitve (Vc) 3,57 l (20,1 %).
English: Tell the person giving you the infusion or get medical help straight away if you experience a reaction during or after any POTELIGEO infusion.
Slovenian: Če med infuzijo zdravila POTELIGEO ali po njej doživite reakcijo, to povejte zdravstvenemu delavcu, ki vam je dal infuzijo, oziroma takoj poiščite zdravniško pomoč.
English: Key secondary endpoints were overall response rate (ORR), ORR after crossover, duration of response (DOR), and changes from baseline of the Skindex-29 Symptoms and Functional Scales, and Functional Assessment of Cancer Therapy-General (FACT-G) Physical and Functional Well-being domains.
Slovenian: Ključni sekundarni opazovani dogodki so bili skupna stopnja odziva (SSO), SSO po zamenjavi zdravila, trajanje odziva (TO) ter spremembe od izhodišča v simptomih in na funkcionalni lestvici
English: Very common Constipation, diarrhoea, nausea, stomatitis
Slovenian: Bolezni prebavil zelo pogosti zaprtost, driska, navzea, stomatitis pogosti bruhanje
English: Administration is weekly on days 1, 8, 15 and 22 of the first 28-day cycle, followed by infusions every two weeks on Days 1 and 15 of each subsequent 28-day cycle until disease progression or unacceptable toxicity.
Slovenian: V prvem 28-dnevnem krogu zdravljenja se zdravilo daje v tedenskih presledkih 1., 8., 15. in 22. dan, temu pa sledijo infuzije v dvotedenskih presledkih 1. in 15. dan vsakega nadaljnjega
English: PFS, months ITT Population IB/II III/IV ITT=intent to treat Paediatric population The European Medicines Agency has waived the obligation to submit the results of studies with mogamulizumab in all subsets of the paediatric population in cutaneous T-cell lymphoma (CTCL) (MF and SS are subtypes of CTCL).
Slovenian: Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z mogamulizumabom za vse podskupine pediatrične populacije s kožnim T-celičnim limfomom (CTCL) (FM in SS sta podtipa CTCL).
English: Mogamulizumab infusion was administered at a dose of 1 mg/kg once weekly for the first 28-day cycle (on Days 1, 8, 15 and 22), and on days 1 and 15 of subsequent 28-day cycles.
Slovenian: V prvem 28-dnevnem krogu zdravljenja so bolniki dobivali infuzije mogamulizumaba v odmerku 1 mg/kg enkrat na teden (1., 8., 15. in 22. dan) in v nadaljnjih
English: Patients receiving mogamulizumab have experienced drug rash (drug eruption), some of which were severe and/or serious.
Slovenian: Pri bolnikih, ki so prejemali mogamulizumab, se je pojavil medikamentozni izpuščaj (kožna reakcija na zdravilo); nekateri primeri so bili hudi in/ali resni.
English: • POTELIGEO should be permanently discontinued for a life-threatening (Grade 4) infusion-related reaction (see section 4.4).
Slovenian: • Ob pojavu življenjsko nevarne reakcije, povezane z infundiranjem (stopnja 4), je treba zdravljenje z zdravilom POTELIGEO trajno opustiti (glejte poglavje 4.4).
English: Uncommon Hepatitis acute, hepatitis
Slovenian: Bolezni jeter, žolčnika in žolčevodov občasni akutni hepatitis, hepatitis
English: Response Rate (n, %) 95% CIa
Slovenian: Stopnja odziva (n, %) 95-odstotni IZa
English: POTELIGEO 4 mg/mL concentrate for solution for infusion.
Slovenian: POTELIGEO 4 mg/ml koncentrat za raztopino za infundiranje
English: Overall response rate (confirmed CR + PR, %) 95% CI
Slovenian: Skupna stopnja odziva (potrjen CR + PR, %) 95-odstotni IZ
English: If you are breast-feeding, you should discuss with your doctor whether you can breast-feed during or after treatment with POTELIGEO.
Slovenian: ali smete dojiti med zdravljenjem z zdravilom POTELIGEO ali po njem.
English: • The infusion of POTELIGEO should be temporarily interrupted for mild to severe (Grades 1-3) infusion-related reactions and symptoms treated.
Slovenian: • Če se pojavijo blage do hude reakcije (stopnje 1-3), povezane z infundiranjem, je treba infundiranje zdravila POTELIGEO začasno prekiniti in zdraviti simptome.
English: How POTELIGEO is given
Slovenian: Kako se daje zdravilo POTELIGEO
English: Response in the viscera could not be evaluated due to limited efficacy data in subjects with visceral involvement; the benefit-risk of mogamulizumab in subjects with visceral involvement is currently undetermined due to lack of data.
Slovenian: Razmerje med koristmi in tveganji mogamulizumaba pri bolnikih s prizadetim drobovjem je trenutno nejasno zaradi pomanjkanja podatkov.
English: Crossover patients received up to 46 months of mogamulizumab therapy, as of December 2016 data cut.
Slovenian: Po podatkih, zbranih do decembra 2016, so se bolniki, ki so zamenjali zdravilo, zdravili z mogamulizumabom največ 46 mesecev.
English: POTELIGEO is a clear to slightly opalescent, colourless solution.
Slovenian: POTELIGEO je bistra do rahlo opalescentna brezbarvna raztopina.
English: The effects of various covariates on the PK s of mogamulizumab were assessed in population PK analyses.
Slovenian: V analizah populacijske farmakokinetike so ocenili učinke različnih kovariatov na farmakokinetiko mogamulizumaba.
English: Patients receiving POTELIGEO have experienced drug rash (drug eruption), some of which were severe and/or serious.
Slovenian: Pri bolnikih, ki so prejemali zdravilo POTELIGEO, se je pojavil medikamentozni izpuščaj (kožna reakcija na zdravilo); nekateri primeri so bili hudi in/ali resni.
English: POTELIGEO contains sodium
Slovenian: OVOJNINAH NALEPKA NA VIALI
English: No adverse effects on male and female reproductive organs were observed in repeat-dose toxicity studies in cynomolgus monkeys (see section 5.3).
Slovenian: V študijah toksičnosti ponavljajočih se odmerkov, ki so jih opravili na opicah pasme Macaca fascicularis, niso ugotovili neželenih učinkov na reproduktivne organe samcev in samic (glejte poglavje 5.3).
English: For patients who test positive for current/previous hepatitis B infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended for advice concerning appropriate measures against hepatitis B reactivation.
Slovenian: Bolnike je treba pred začetkom zdravljenja z mogamulizumabom testirati za okužbo z virusom hepatitisa B. Bolnikom s pozitivnim testom za sedanjo/preteklo okužbo s hepatitisom B se priporoča, da se posvetujejo z zdravnikom, ki ima strokovno znanje o zdravljenju hepatitisa B, glede ustreznih ukrepov za preprečevanje ponovne aktivacije hepatitisa B. Zapleti pri alogenski presaditvi hematopoetskih matičnih celic (HSCT) po zdravljenju z mogamulizumabom Pri bolnikih s T-celičnimi limfomi, razen FM ali SS, pri katerih so po zdravljenju z mogamulizumabom opravili presaditev hematopoetskih matičnih celic (HSCT), so poročali o zapletih,
English: Sodium hydroxide (for pH adjustment) Hydrochloric acid (for pH adjustment) Water for injections
Slovenian: FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi citronska kislina monohidrat glicin polisorbat 80 natrijev hidroksid (za prilagoditev vrednosti pH) klorovodikova kislina (za prilagoditev vrednosti pH) voda za injekcije
English: Very common Headache
Slovenian: Bolezni živčevja zelo pogosti glavobol
English: Injury, poisoning and procedural complications
Slovenian: Poškodbe, zastrupitve in zapleti pri posegih zelo pogosti reakcija, povezana z infundiranjem
English: Anaemia, neutropenia, leukopenia, Thrombocytopenia
Slovenian: Bolezni krvi in limfatičnega sistema pogosti anemija, nevtropenija, levkopenija, trombocitopenija
English: The majority of IRRs occur during or shortly after the first infusion (all within 24 hours of administration), with the incidence decreasing over subsequent treatments.
Slovenian: (v 24 urah po dajanju zdravila), nato pa se pojavnost pri nadaljnjih krogih zdravljenja zmanjšuje.
English: - fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness and/or muscle or joint pain.
Slovenian: epileptični napadi, neenakomeren srčni utrip, temen ali moten urin, nenavadna utrujenost in/ali bolečine v mišicah ali sklepih.
English: See section 4.2 for dose modification information.
Slovenian: Informacije o prilagoditvah odmerjanja so v poglavju 4.2.
English: Overall response rate (confirmed CR + PR, %) 95% CI P-valuea Viscera n=6
Slovenian: Skupna stopnja odziva (potrjen CR + PR, %) 95-odstotni IZ Vrednost Pa Drobovje n = 6
English: Overall response rate (confirmed CR + PR, %)
Slovenian: Skupna stopnja odziva (potrjen PO + DO, %)
English: No clinically important differences in the clearance of mogamulizumab were found between patients with mild to severe renal impairment and patients with normal renal function.
Slovenian: Med bolniki z blago do hudo okvaro ledvic in bolniki z normalnim delovanjem ledvic ni bilo klinično pomembnih razlik v očistku mogamulizumaba.
English: No clinically important differences in the clearance of mogamulizumab were found between patients with mild to moderate hepatic impairment and patients with normal hepatic function.
Slovenian: Med bolniki z blago do zmerno okvaro jeter in bolniki z normalnim delovanjem jeter niso ugotovili klinično pomembnih razlik v očistku mogamulizumaba.
English: Of the patients randomised to vorinostat, 136 patients (73.1%) crossed over to mogamulizumab during the study.
Slovenian: Med bolniki, ki so bili naključno razvrščeni v skupino z vorinostatom, je med študijo 136 bolnikov
English: Warnings and precautions Talk to your doctor or nurse before using POTELIGEO if you:
Slovenian: Pred začetkom uporabe zdravila POTELIGEO se posvetujte z zdravnikom ali medicinsko sestro:
English: Overall response rate (confirmed CR + PR, %) 95% CI P-valuea Lymph nodes n=136
Slovenian: Skupna stopnja odziva (potrjen PO + DO, %) 95-odstotni IZ Vrednost Pa Bezgavke n = 136
English: - signs of infection, which may include a fever, sweats or chills, flu-like symptoms, sore throat or difficulty swallowing, cough, shortness of breath, stomach pain, nausea or vomiting, diarrhoea and feeling very unwell.
Slovenian: Zdravnik lahko ukine vaše zdravljenje z zdravilom POTELIGEO, če imate hudo reakcijo nanj; - znaki okužbe, ki lahko vključujejo zvišano telesno temperaturo, znojenje ali mrazenje, gripi podobne simptome, vneto grlo ali težave pri požiranju, kašelj, zasoplost, bolečine v želodcu, siljenje na bruhanje ali bruhanje, drisko in zelo slabo počutje; - kožne bolečine, srbenje, mehurji na koži, kožni izpuščaj ali bolečina v ustih, ki so morda znaki,
English: POTELIGEO should be administered within 2 days of the scheduled day.
Slovenian: Dajanje zdravila POTELIGEO sme odstopati od načrtovanega dneva za največ dva dni.
English: • Visually inspect the medicinal product for particulate matter and discolouration prior to administration.
Slovenian: • Pred uporabo raztopino preverite ter se prepričajte, da ne vsebuje delcev in ni obarvana.
English: Acute infusion-related reactions (IRRs) have been observed in patients treated with mogamulizumab.
Slovenian: Pri bolnikih, zdravljenih z mogamulizumabom, so opazili akutne reakcije, povezane z infundiranjem.
English: Less than 1% of patients treated in Study 0761-010 discontinued treatment due to infusion-related reactions.
Slovenian: Zaradi reakcij, povezanih z infundiranjem, se je prenehalo zdraviti manj kot 1 % bolnikov v študiji
English: - chills, nausea or vomiting, headache, wheezing, itching, flushing, rash, dizziness or feeling faint, difficulty breathing and fever, which may be signs of an infusion reaction.
Slovenian: omotica ali občutek, da boste omedleli, oteženo dihanje in zvišana telesna temperatura, ki so lahko znaki reakcije na infuzijo.
English: - skin pain, itching, skin blisters, skin rash or sore mouth, which are possible signs that you may be developing a severe skin reaction, such as Stevens-Johnson syndrome or toxic epidermal necrolysis.
Slovenian: da se razvija huda kožna reakcija, kot sta Stevens-Johnsonov sindrom ali toksična epidermalna nekroliza;
English: • POTELIGEO should be permanently discontinued for a life-threatening (Grade 4) rash (see section 4.4).
Slovenian: POTELIGEO trajno opustiti (glejte poglavje 4.4).
English: Polysorbate 80
Slovenian: Bloemlaan 2
English: Clear to slightly opalescent, colourless solution.
Slovenian: POTELIGEO je bistra brezbarvna raztopina.
English: Endocrine disorders
Slovenian: Organski sistem
English: Uncommon Tumour lysis syndrome
Slovenian: Presnovne in prehranske motnje občasni sindrom tumorske lize
English: - ever had an infusion reaction with this medicine (possible symptoms of an infusion reaction are listed in section 4).
Slovenian: - če ste kdaj imeli hudo kožno reakcijo na to zdravilo; - če ste kdaj imeli reakcijo na infuzijo tega zdravila (možni simptomi reakcije, povezane z infuzijo, so navedeni v poglavju 4); - če imate virus humane imunske pomanjkljivosti (HIV), herpes, citomegalovirus (CMV), okužbo s hepatitisom B ali C ali drugo okužbo, ki se še ni pozdravila;
English: Blood and lymphatic system disorders
Slovenian: Bolezni endokrinega sistema pogosti hipotiroidizem
English: • If you have any questions, speak with your doctor or pharmacist.
Slovenian: • Če imate kakršna koli vprašanja, se posvetujte z zdravnikom ali farmacevtom.
English: It is currently available in the European Union (EU) in a number of different formulations.
Slovenian: Trenutno je v Evropski uniji (EU) na voljo v več različnih farmacevtskih oblikah.
English: The review of systemic diclofenac was initiated on 31 October 2012 at the request of the United Kingdom medicines agency, under Article 31 of Directive 2001/83/EC.
Slovenian: Pregled sistemskega diklofenaka se je začel dne 31. oktobra 2012 na zahtevo agencije Združenega kraljestva za zdravila v skladu s členom 31 Direktive 2001/83/ES.
English: • You should not stop taking your treatment without talking to your doctor.
Slovenian: • Zdravila ne smete prenehati jemati, ne da bi se prej posvetovali z zdravnikom.
English: Limitations in the data had made it hard to quantify the risk initially, but a consistent picture was emerging by the time of the 2012 review.
Slovenian: Zaradi pomanjkljivosti podatkov je bilo najprej težko kvantificirati tveganje, vendar se je do pregleda leta 2012 že pojavila dosledna slika.
English: The product information will be amended and healthcare professionals prescribing or dispensing systemic diclofenac will receive further appropriate communication at a national level.
Slovenian: Informacije o zdravilu bodo spremenjene, zdravstveni delavci, ki predpisujejo ali izdajajo sistemski diklofenak, pa bodo prejeli dodatna ustrezna obvestila na nacionalni ravni.
English: The safety of NSAIDs has been closely monitored by regulatory authorities in the EU.
Slovenian: Varnost teh zdravil podrobno spremljajo regulativni organi v EU.
English: New measures aim to minimise cardiovascular risks
Slovenian: Novi ukrepi so namenjeni zmanjšanju srčno-žilnih tveganj
English: The latter found that, compared with placebo, the risk of major vascular events was increased by about one third by a COX-2 inhibitor (rate ratio [RR] 1.37, 95% confidence interval [CI] 1.14-1.66; p=0.0009) or diclofenac (1.41, 1.12-1.78; p=0.0036), mainly due to an increase in major coronary events (coxibs: 1.76, 1.312.37; p=0.0001; diclofenac: 1.70, 1.19-2.41; p=0.0032).
Slovenian: V tej analizi so ugotovili, da se je v primerjavi s placebom tveganje za večje vaskularne dogodke povečalo za približno eno tretjino pri uporabi zaviralca COX-2 (razmerje stopnje [RS] 1,37, 95-odstotni interval zaupanja [IZ] 1,14-1,66; p = 0,0009) ali diklofenaka (1,41, 1,12-1,78; p = 0,0036), v glavnem zaradi povečanja števila večjih koronarnih dogodkov (koksibi: 1,76, 1,31-2,37; p = 0,0001; diklofenak: 1,70, 1,19-2,41; p = 0,0032).
English: Diclofenac-containing medicines have been authorised by national approval procedures in the EU Member States and have been available for many years under a wide range of trade names.
Slovenian: Zdravila, ki vsebujejo diklofenak, so bila v državah članicah EU odobrena po nacionalnih postopkih in so že več let na voljo pod vrsto različnih trgovskih imen.
English: This applies particularly when diclofenac is used at a high dose and for long-term treatment.
Slovenian: To velja predvsem, kadar se diklofenak uporablja pri velikih odmerkih za dolgoročno zdravljenje.
English: About 8 people in 1,000 at moderate risk of heart disease are likely to have a heart attack over one year.
Slovenian: Približno 8 od 1.000 ljudi, pri katerih obstaja zmerno tveganje za bolezen srca, utegne utrpeti možgansko kap v obdobju enega leta.
English: • The effectiveness of diclofenac is well established.
Slovenian: • Učinkovitost diklofenaka je bila dokazana.
English: As diclofenac-containing medicines are all authorised nationally, the PRAC recommendations were sent to the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh), which adopted a final position.
Slovenian: Ker so vsa zdravila, ki vsebujejo diklofenak, odobrena na nacionalni ravni, so bila priporočila odbora PRAC posredovana Usklajevalni skupini za postopek z medsebojnim priznavanjem in decentralizirani postopek - zdravila za uporabo v humani medicini (CMDh), ki je sprejela dokončno stališče.
English: New safety advice for diclofenac
Slovenian: Nova priporočila za varno uporabo diklofenaka
English: It belongs to a group of medicines called ‘non-steroidal anti-inflammatory drugs' (NSAIDs).
Slovenian: Spada v skupino zdravil, imenovanih nesteroidna protivnetna zdravila (NSAID).
English: The latest review by the PRAC was therefore initiated specifically to assess the benefit-risk of systemic diclofenac.
Slovenian: Zadnji pregled, ki ga je opravil odbor PRAC, se je torej začel posebej za to, da se oceni razmerje med tveganji in koristmi sistemskega diklofenaka.
English: The CMDh position was sent to the European Commission, which confirmed it and took a final legally binding decision throughout the EU on 25 September 2013.
Slovenian: Stališče skupine CMDh je bilo posredovano Evropski komisiji, ki ga je potrdila in dne 25. septembra 2013 sprejela končen pravno zavezujoč sklep, veljaven po vsej EU.
English: • If you are on long-term diclofenac treatment you will need to have your treatment reviewed to ensure that it is still right for you.
Slovenian: • Če vam je bilo predpisano dolgoročno zdravljenje z diklofenakom, bo treba ponovno oceniti zdravljenje in se prepričati, ali je to še vedno primerno za vas.
English: Diclofenac is effective in reducing inflammation and pain.
Slovenian: Diklofenak je učinkovit pri zmanjšanju vnetja in bolečine.
English: Overall, compared with placebo, allocation to diclofenac or a coxib caused around three additional major vascular events per 1,000 participants per year, with one such event causing death; in high-risk individuals, about seven or eight more would have a major vascular event, of which two would be fatal.
Slovenian: Na splošno sta diklofenak ali koksib v primerjavi s placebom povzročila približno tri dodatne večje vaskularne dogodke na 1.000 sodelujočih posameznikov na leto, pri čemer se je eden od teh dogodkov končal s smrtjo; med populacijo z velikim tveganjem bi bilo sedem ali osem posameznikov več z večjim vaskularnim dogodkom, od katerih bi bila dva smrtna.
English: Since some prostaglandins are involved in causing pain and inflammation at sites of injury or damage in the body, a reduced production of prostaglandins reduces pain and inflammation.
Slovenian: Ker nekateri prostaglandini sodelujejo pri povzročanju bolečine in vnetja na mestih poškodb ali okvar v telesu, se z zmanjšanjem nastajanja prostaglandinov zmanjšata tudi bolečina in vnetje.
English: The overall number of heart attacks in people at moderate risk would be expected to increase by around 3 cases per year for every 1,000 people treated with diclofenac (to 11 per 1,000 people per year).
Slovenian: Skupno število srčnih kapi pri ljudeh, pri katerih obstaja zmerno tveganje, bi se verjetno povečalo za približno 3 primere na leto za vsakih 1.000 ljudi, zdravljenih z diklofenakom (na 11 od 1.000 ljudi na leto).
English: A class warning of this risk is in place and the product information for all NSAIDs recommends that these medicines be used at the lowest effective dose for the shortest period of time necessary to control symptoms.
Slovenian: Za to skupino je bilo izdano opozorilo o omenjenem tveganju, informacije o zdravilu za vsa nesteroidna protivnetna zdravila pa vsebujejo priporočilo, naj se ta zdravila uporabljajo pri najmanjšem učinkovitem odmerku in najkrajši možni čas, ki je potreben za obvladanje simptomov.
English: As the CMDh position was adopted by majority it was sent to the European Commission, which confirmed it and took a final legally binding decision valid throughout the EU.
Slovenian: Ker je skupina CMDh omenjeno stališče sprejela z večino, je bilo posredovano Evropski komisiji, ki ga je potrdila in sprejela končen pravno zavezujoč sklep, veljaven po vsej EU.
English: Although the risk is likely to be dose-dependent, the PRAC considered that cardiovascular thrombotic risk cannot be excluded across all doses of diclofenac, especially in patients with pre-existing co-morbidities.
Slovenian: Čeprav je tveganje verjetno odvisno od odmerka, je PRAC menil, da srčno-žilnega trombotičnega tveganja ni mogoče izključiti za vse odmerke diklofenaka, zlasti ne pri bolnikih s predhodno obstoječimi sočasnimi obolenji.
English: • As the cardiovascular risks of diclofenac may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used.
Slovenian: • Ker se srčno-žilna tveganja, povezana z diklofenakom, povečujejo z odmerkom in trajanjem izpostavljenosti, je treba diklofenak uporabljati čim krajši čas in pri najmanjšem učinkovitem dnevnem odmerku.
English: • If you have other risk factors such as high blood pressure, high blood cholesterol, diabetes, or if you smoke, your doctor will need to assess if you should use diclofenac and the best way to take it.
Slovenian: • Če imate druge dejavnike tveganja, kot so visok krvni tlak, visoke ravni holesterola v krvi in sladkorna bolezen, ali če kadite, bo zdravnik moral oceniti, ali lahko uporabljate diklofenak in na kakšen način.
English: The new advice aims to minimise the risks of effects on the heart and circulation from these medicines.
Slovenian: Z novimi priporočili se želi zmanjšati tveganja, povezana z učinki, ki jih imajo ta zdravila na srce in ožilje.
English: The patient's need for symptomatic relief and response to therapy should be re-evaluated periodically.
Slovenian: Občasno je treba ponovno oceniti potrebo bolnika po lajšanju simptomov in njegov odziv na zdravljenje.
English: • The risk with diclofenac is increased more if you are already at higher risk, so use is no longer recommended if you have already had a heart attack or stroke, or have heart failure, blockages to blood vessels to the heart or brain or an operation to clear or bypass such blockages, or circulatory problems that restrict blood flow to your limbs.
Slovenian: • Tveganje pri uporabi diklofenaka se še poveča, če ste že izpostavljeni večjemu tveganju, zato se uporaba ne priporoča, če ste kdaj imeli srčno ali možgansko kap, če imate srčno popuščanje ali zamašene krvne žile, ki oskrbujejo srce ali možgane, če ste imeli operacijo za sprostitev ali premostitev zamašenih žil ali če imate težave z ožiljem, ki ovirajo dotok krvi v ude.